Cargando…

Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma

HER2+/ER+ breast cancer, a subset of the luminal B subtype, makes up approximately 10% of all breast cancers. The bidirectional crosstalk between HER2 and estrogen receptor (ER) in HER2+/ER+ breast cancer contributes to resistance towards both anti-estrogens and HER2-targeted therapies. TFF3 promote...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chong, Qing-Yun, You, Ming-Liang, Pandey, Vijay, Banerjee, Arindam, Chen, Yi-Jun, Poh, Han-Ming, Zhang, Mengyi, Ma, Lan, Zhu, Tao, Basappa, Salundi, Liu, Liang, Lobie, Peter E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650333/ https://www.ncbi.nlm.nih.gov/pubmed/29088778 http://dx.doi.org/10.18632/oncotarget.18431

Ejemplares similares

A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma
por: Zhang, Mengyi, et al.
Publicado: (2019)

Trefoil Factor-3 (TFF3) Stimulates De Novo Angiogenesis in Mammary Carcinoma both Directly and Indirectly via IL-8/CXCR2
por: Lau, Wai-Hoe, et al.
Publicado: (2015)

Inhibition of TFF3 Enhances Sensitivity—and Overcomes Acquired Resistance—to Doxorubicin in Estrogen Receptor-Positive Mammary Carcinoma
por: Poh, Han Ming, et al.
Publicado: (2019)

Circulating Serum Trefoil Factor 3 (TFF3) Is Dramatically Increased in Chronic Kidney Disease
por: Du, Ting-yi, et al.
Publicado: (2013)

Trefoil Factor 3 (TFF3) Is Involved in Cell Migration for Skeletal Repair
por: Krüger, Katharina, et al.
Publicado: (2019)

The Urinary Concentration of Trefoil Factor 3 (TFF3) in the Term and Preterm Neonates
por: Kamianowska, Monika, et al.
Publicado: (2023)

Deficiency in trefoil factor 1 (TFF1) increases tumorigenicity of human breast cancer cells and mammary tumor development in TFF1-knockout mice
por: Buache, E, et al.
Publicado: (2011)

Overexpression of trefoil factor 3 (TFF3) contributes to the malignant progression in cervical cancer cells
por: Yuan, Zhaohu, et al.
Publicado: (2017)

Trefoil Factor 3 (TFF3) Is Regulated by Food Intake, Improves Glucose Tolerance and Induces Mucinous Metaplasia
por: Ge, Hongfei, et al.
Publicado: (2015)

Novel Biphenyl Amines Inhibit Oestrogen Receptor (ER)-α in ER-Positive Mammary Carcinoma Cells
por: Basappa, Basappa, et al.
Publicado: (2021)

Human Synovia Contains Trefoil Factor Family (TFF) Peptides 1–3 Although Synovial Membrane Only Produces TFF3: Implications in Osteoarthritis and Rheumatoid Arthritis
por: Popp, Judith, et al.
Publicado: (2019)

Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma
por: Pandey, Vijay, et al.
Publicado: (2014)

Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent
por: You, Ming-Liang, et al.
Publicado: (2017)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer
por: Li, Xin, et al.
Publicado: (2018)

Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK
por: Chen, Ru-Mei, et al.
Publicado: (2019)

Trefoil factor 3 promotes pancreatic carcinoma progression via WNT pathway activation mediated by enhanced WNT ligand expression
por: Cheng, Feifei, et al.
Publicado: (2022)

Effect of Tff3 Deficiency and ER Stress in the Liver
por: Šešelja, Kate, et al.
Publicado: (2019)

Strategic Trastuzumab Mediated Crosslinking Driving Concomitant HER2 and HER3 Endocytosis and Degradation in Breast Cancer
por: Wymant, Jennifer Mary, et al.
Publicado: (2020)

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
por: Li, Shuai, et al.
Publicado: (2021)

Effect of Initial Periodontal Therapy on Salivary Trefoil Factor (TFF3) in otherwise Healthy Patients with Gingivitis and Chronic Periodontitis
por: Meesala, Devika, et al.
Publicado: (2018)

Predictive value of quantitative HER2, HER3 and p95HER2 levels in HER2-positive advanced breast cancer patients treated with lapatinib following progression on trastuzumab
por: Duchnowska, Renata, et al.
Publicado: (2017)

Hypomethylation associated enhanced transcription of trefoil factor-3 mediates tamoxifen-stimulated oncogenicity of ER+ endometrial carcinoma cells
por: Pandey, Vijay, et al.
Publicado: (2017)

Forced Trefoil Factor Family Peptide 3 (TFF3) Expression Reduces Growth, Viability, and Tumorigenicity of Human Retinoblastoma Cell Lines
por: Große-Kreul, Jan, et al.
Publicado: (2016)

Targeting HER3 or MEK overcomes acquired Trastuzumab resistance in HER2-positive gastric cancer-derived xenograft
por: Zhang, Mengqi, et al.
Publicado: (2022)

Trefoil Factor Family Member 2 (TFF2) as an Inflammatory-Induced and Anti-Inflammatory Tissue Repair Factor
por: Ghanemi, Abdelaziz, et al.
Publicado: (2020)

Expression of MUC5AC and Trefoil Peptide 1 (TFF1) in the Subtypes of Intestinal Metaplasia
por: Song, Joo-Yong, et al.
Publicado: (2012)

Salivary Trefoil Factor Family (TFF) Peptides and Their Roles in Oral and Esophageal Protection: Therapeutic Potential
por: Hoffmann, Werner
Publicado: (2021)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Obstructive sleep apnea and rhonchopathy are associated with downregulation of trefoil factor family peptide 3 (TFF3)—Implications of changes in oral mucus composition
por: Siber-Hoogeboom, Regina, et al.
Publicado: (2017)

Salivary trefoil factor family peptide 3 (TFF3) and flow rate in persons with and without obstructive sleep apnea: A preliminary study
por: Ruangsri, Supanigar, et al.
Publicado: (2023)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
por: Ishimine, Yu, et al.
Publicado: (2015)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Trefoil Factor Family (TFF) Peptides and Their Links to Inflammation: A Re-evaluation and New Medical Perspectives
por: Hoffmann, Werner
Publicado: (2021)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
por: Maadi, Hamid, et al.
Publicado: (2018)

Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
por: Burguin, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9i37esbsj30pj873gvhkc63oa5